WiseOwl research report out with spec buy up to 8.2c
http://www.analyticamedical.com/downloads/2012/20121220-WiseOwl-Analytica.pdf
Expect revenues in Q3 of 2013 and value the Brazillian deal to be worth $3M per annum.
Would make ALT cashflow positive.
Great news